Matthew James Wolan

Mr. Matthew James Wolan

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
GPGorana Puzovic
Gorana Puzovic
MWMatthew James Wolan
Matthew James Wolan
YSYonggong Shi
Yonggong Shi
GCGregory T. Collins
Gregory T. Collins

8 September 2026 in Kinases and Phosphatases
Verified
Journal Article
Open access
PDF file
JNJoel Karikari Nyarkoh
Joel Karikari Nyarkoh
MWMatthew James Wolan
Matthew James Wolan
DFDavid Feliciano
David Feliciano
The phosphotransferase activity of the protein kinase known as the mechanistic Target of Rapamycin (mTOR) is arguably one of the most studied biochemical events in biomedical sciences because of its importance to human health and evolution. Despite progress being made in understanding the structure, biochemical characteristics, and function of the enzyme, tremendous knowledge gaps remain unfilled. Altered mTOR activity occurs in numerous neurological disorders, including those that present with seizures and neoplasms. Advances in cancer biology have identified that neuron activity is a critical driver of neoplastic growth. Here, we discuss mTOR, examples of neoplasms with altered neuron activity, and the potential utility of using mTOR inhibitors to modulate tumor-associated neurons.